Skip to content

Pharmaceuticals

ISSN 1424-8247

72 papers in the library · 565 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review

Pharmaceuticals April 1, 2023 Aleksander Kwaśny, A. Włodarczyk, Damian Ogonowski et al. 27 citations

Background: Depression is a debilitating disease with a high socioeconomic burden. Regular antidepressants usually require several weeks to ameliorate symptoms; however, numerous patients do not achieve remission. What is more, sleep disturbances are one of the most common residual symptoms. Ketamine is a novel antidepressant with rapid onset of action with a proven antisuicidal effect. Little...

The Antidepressant-like Activity and Cognitive Enhancing Effects of the Combined Administration of (R)-Ketamine and LY341495 in the CUMS Model of Depression in Mice Are Related to the Modulation of Excitatory Synaptic Transmission and LTP in the PFC

Pharmaceuticals February 1, 2023 Agnieszka Pałucha-Poniewiera, B. Bobula, Anna Rafało-Ulińska

(S)-Ketamine is the first rapid-acting antidepressant drug (RAAD) introduced for the treatment of depression. However, research is still being carried out on the search for further RAADs that will be not only effective but also safe to use. Recent data have indicated that the combined administration of (R)-ketamine and the mGlu2/3 receptor antagonist LY341495 (mixRL) induces rapid and sustained...

Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms

Pharmaceuticals January 24, 2023 Adam Włodarczyk, Alicja Dywel, Wiesław Jerzy Cubała 10 citations

There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety concerns arise regarding adverse drug reactions in specific subpopulations. The aim of this study was to investigate the safety of intravenous ketamine treatment in relation to dissociative and psychotic measures in TRD inpatients with Major Depressive Disorder (MDD) and Bipolar depression (BP) with...

Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?

Pharmaceuticals December 31, 2022 Antonio Munafò, Davide Arillotta, Guido Mannaioni et al. 15 citations

Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation of depressive symptoms. However, to date, there have been several study limitations (e.g., small sample sizes, blinding, limited follow-up,...

A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe.

Pharmaceuticals December 28, 2022 Raphaël Serreau, Ammar Amirouche, Amine Benyamina et al. 13 citations

Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various Psilocybe-type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the need to develop simple and...

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression.

Pharmaceuticals December 26, 2022 Lorena Catarina Del Sant, Luciana Maria Sarin, Ana Cecília Lucchese et al.

Esketamine has been approved by the US Food and Drug Administration (FDA) as an adjunctive treatment for use in conjunction with an oral antidepressant for patients with treatment-resistant depression (TRD), but dissociative symptoms are common adverse effects. A retrospective analysis of 394 subcutaneous esketamine injections given to 70 patients with TRD that were administered once a week...

4-Isobutylmethcathinone—A Novel Synthetic Cathinone with High In Vitro Cytotoxicity and Strong Receptor Binding Preference of Enantiomers

Pharmaceuticals November 30, 2022 Martin Paškan, Silvie Rimpelová, Vladimíra Svobodová Pavlíčková et al. 9 citations

New psychoactive substances and among them synthetic cathinones represent a significant threat to human health globally. However, within such a large pool of substances derived from a natural compound ((S)-cathinone), substances with important pharmaceutical uses can be identified, as already documented by bupropione. Therefore, this work aimed to find a synthetic pathway for a novel synthetic...

DOI: 10.3390/ph15121495 (opens in new tab) Serotonin Cathinone Cytotoxicity Enantiomer +7

"K-Powder" Exposure during Adolescence Elicits Psychiatric Disturbances Associated with Oxidative Stress in Female Rats.

Pharmaceuticals November 9, 2022 Sabrina de Carvalho Cartágenes, Cinthia Cristina Sousa de Menezes Da Silveira, Bruno Gonçalves Pinheiro et al.

Ketamine, also called 'K-powder' by abusers, an analog of phencyclidine, primarily acts as an antagonist of N-methyl-D-aspartic acid (NMDA) receptors, therapeutically used as an anesthetic agent. Ketamine also stimulates the limbic system, inducing hallucinations and dissociative effects. At sub-anesthetic doses, ketamine also displays hallucinatory and dissociative properties, but not loss of...

New Paradigms of Old Psychedelics in Schizophrenia

Pharmaceuticals May 23, 2022 Danish Mahmood, Sattam Khulaif Alenezi, Md Jamir Anwar et al. 29 citations

Psychedelics such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline exhibit intense effects on the human brain and behaviour. In recent years, there has been a surge in studies investigating these drugs because clinical studies have shown that these once banned drugs are well tolerated and efficacious in medically supervised low doses called microdosing....

Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism

Pharmaceuticals January 21, 2022 Anna Rafało-Ulińska, P. Brański, Agnieszka Pałucha-Poniewiera

Ketamine is an effective, rapid-acting antidepressant drug (RAAD), but it induces side effects. To overcome these challenges, attempts have been made to use safer enantiomer ((R)-ketamine) or mGlu2/3 receptor antagonists, which induce ketamine-like effects and enhance its action. Here, we propose combining these two strategies to investigate the antidepressant-like effects of low doses of two...

Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors

Pharmaceuticals November 24, 2021 Robertas Strumila, Bénédicte Nobile, Laura Korsakova et al. 35 citations

The available interventions for people who are at risk of suicide have limited efficacy. Recently, research on new mental health treatments has started to consider psychedelic compounds, particularly psilocybin, a molecule with a few thousand years of history of use in human societies. The possible effects of psilocybin on suicidal ideation and behaviors have not been specifically studied yet;...

DOI: 10.3390/ph14121213 (opens in new tab) Psilocybin Suicidal ideation Hallucinogen Clinical psychology +3

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

Pharmaceuticals September 28, 2021 René Zeiss, Maximilian Gahr, Heiko Graf 17 citations

There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD). Several state-of-the-art studies have provided new insight into the mechanisms of action of psilocybin and its therapeutic potential. Nevertheless, many questions remain unanswered. With this review, we...

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review

Pharmaceuticals August 12, 2021 Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza et al. 30 citations

Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this...

Magnesium in Ketamine Administration in Treatment-Resistant Depression

Pharmaceuticals May 3, 2021 Natalia Górska, Wiesław Jerzy Cubała, Jakub Słupski et al. 2 citations

Relationship between depression and magnesium levels is reported. This observational study examined whether serum magnesium concentration change over time of ketamine treatment course, also whether association between magnesium concentrations and treatment response measured with Montgomery-Åsberg Depression Rating Scale (MADRS) score occurs. Moreover, interlink between changes in Young Mania...

DOI: 10.3390/ph14050430 (opens in new tab) Ketamine Magnesium Depression economics Mania +7

Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects

Pharmaceuticals February 3, 2021 Andreia Machado Brito-Da-Costa, Áurea Madureira-Carvalho, Diana Dias Da Silva et al. 42 citations

Salvia divinorum Epling and Játiva is a perennial mint from the Lamiaceae family, endemic to Mexico, predominantly from the state of Oaxaca. Due to its psychoactive properties, S. divinorum had been used for centuries by Mazatecans for divinatory, religious, and medicinal purposes. In recent years, its use for recreational purposes, especially among adolescents and young adults, has...

DOI: 10.3390/ph14020116 (opens in new tab) Hallucinogen Pharmacology Traditional medicine Drug

Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans

Pharmaceuticals January 28, 2021 Esther Papaseit, Eulàlia Olesti, Clara Pérez‐mañá et al. 30 citations

Mephedrone (4-methylmethcathinone) is a synthetic cathinone with psychostimulant properties which remains one of the most popular new psychoactive substances (NPS). It is frequently used orally and/or intranasally. To date, no studies have evaluated the acute effects and pharmacokinetics after self-administration of mephedrone orally (ingestion) and intranasally (insufflation) in naturalistic...

DOI: 10.3390/ph14020100 (opens in new tab) Mephedrone Cathinone Nasal administration Pharmacology +8

Automated GMP-Compliant Production of [68Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans

Pharmaceuticals August 1, 2020 Michael Wagner, Johan G. Doverfjord, Joachim Tillner et al.

Introduction: [68Ga]Ga-DO3A-VS-Cys40-Tuna-2 (previously published as [68Ga]Ga-DO3A-VS-Cys40-S01-GCG) has shown high-affinity specific binding to the glucagon receptor (GCGR) in vitro and in vivo in rats and non-human primates in our previous studies, confirming the suitability of the tracer for drug development applications in humans. The manufacturing process of [68Ga]Ga-DO3A-VS-Cys40-Tuna-2...

DOI: 10.3390/ph13080176 (opens in new tab) Full text (opens in new tab) Glucagon receptor Diabetes Gmp Gallium-68 +2

Safety of Repeated Administration of Parenteral Ketamine for Depression

Pharmaceuticals July 13, 2020 David Feifel, David Dadiomov, Kelly C. Lee

The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to...

The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression

Pharmaceuticals September 11, 2019 Brittany O’brien, Marijn Lijffijt, Allison Wells et al.

Childhood maltreatment is associated with a poor treatment response to conventional antidepressants and increased risk for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor (NDMAR) antagonist ketamine has been shown to rapidly improve symptoms of depression in patients with TRD. It is unknown if childhood maltreatment could influence ketamine’s treatment response. We...

Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation

Pharmaceuticals July 5, 2011 Elena Puerta, Norberto Aguirre 6 citations

The amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is widely abused as a recreational drug due to its unique psychological effects. Of interest, MDMA causes long-lasting deficits in neurochemical and histological markers of the serotonergic neurons in the brain of different animal species. Such deficits include the decline in the activity of tryptophan hydroxylase in...

Cocaine and MDMA Induce Cellular and Molecular Changes in Adult Neurogenic Systems: Functional Implications

Pharmaceuticals June 17, 2011 Vivian Capilla‐González, Vicente Hernández‐rabaza 4 citations

The capacity of the brain to generate new adult neurons is a recent discovery that challenges the old theory of an immutable adult brain. A new and fascinating field of research now focuses on this regenerative process. The two brain systems that constantly produce new adult neurons, known as the adult neurogenic systems, are the dentate gyrus (DG) of the hippocampus and the lateral...

Neuronal Nicotinic Receptors as New Targets for Amphetamine-Induced Oxidative Damage and Neurotoxicity

Pharmaceuticals June 15, 2011 Elena Escubedo, Sara Garcia-Ratés, Jordi Camarasa et al. 4 citations

Amphetamine derivatives such as methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) are widely abused drugs in a recreational context. This has led to concern because of the evidence that they are neurotoxic in animal models and cognitive impairments have been described in heavy abusers. The main targets of these drugs are plasmalemmal and vesicular monoamine...

DOI: 10.3390/ph4060822 (opens in new tab) Full text (opens in new tab) MDMA Methamphetamine Nicotinic Neuroprotection +1